Vernalis achieves milestone with Servier
Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on achieving the target. In addition, Vernalis will receive fees and a share in
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.